BioCorRx
601 North Parkcenter Drive
Suite 103
Santa Ana
California
92705
United States
Tel: 512-267-2430
Website: http://bicxcorp.com/
Email: investors@BioCorRx.com
About BioCorRx
BioCorRx, Inc. (OTC: BICX) is a healthcare solutions company on the leading edge of addiction treatment. The company has developed a treatment program that is used by various independently owned treatment centers throughout the United States to treat alcoholism and opioid addiction.The program consists of two components:
BioCorRx, Inc. has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol or opioids for several months and as long as a year in some patients, depending on individual metabolism rates.
BioCorRx, Inc. also developed a counseling program that is tailored specifically to help those afflicted with addiction addicts prepare for life without abuse of their desired substance. Once a patient has received the implant, they are encouraged to enter the counseling program to maximize results.
BioCorRx, Inc.’s revolutionary addiction treatment program has a very high success rate as reported by patients in routine telephone and face to face interviews conducted by clinics using the program. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private counseling program without co-workers or family members knowing.
YEAR FOUNDED:
1999
LEADERSHIP:
CEO: Brady Granier
58 articles about BioCorRx
-
BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
4/3/2024
BioCorRx Inc. today announced that its subsidiary BioCorRx Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, has been granted a new patent by the United States Patent and Trademark Office (USPTO).
-
BioCorRx Reports Business Update for 2023
4/2/2024
BioCorRx Inc. today provided a business update for the year ended December 31, 2023, and reported on recent corporate developments.
-
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
2/8/2024
BioCorRx Inc. announced that its subsidiary BioCorRx Pharmaceuticals Inc., has appointed Kate Beebe DeVarney, Ph.D. to its Board of Directors.
-
BioCorRx Reports Business Update for the Third Quarter of 2023
11/14/2023
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended September 30, 2023, and reported on recent corporate developments.
-
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
8/15/2023
BioCorRx Inc. (OTCQB: BICX) (the “Company”) today announced its submission to the US Food and Drug Administration (FDA) of an expanded access program application for BICX104 (implantable naltrexone pellet) for the treatment of opioid use disorder (OUD) patients that meet program eligibility criteria.
-
BioCorRx Reports Business Update for the Second Quarter of 2023
8/14/2023
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the three months ended June 30, 2023, and reported on recent corporate developments.
-
BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
7/18/2023
BioCorRx Inc. today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).
-
BioCorRx Provides Business Update for the First Quarter of 2023
5/16/2023
BioCorRx Inc. today provided a business update for the three months ended March 31, 2023 and reported on recent corporate developments.
-
BioCorRx Provides Business Update for 2022
4/3/2023
BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the year ended December 31, 2022 and reported on recent corporate developments.
-
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
3/7/2023
BioCorRx Inc.(OTCQB: BICX) (the “Company”), a clinical-stage developer and provider of innovative treatment programs for substance use and related disorders, has announced interim positive safety and pharmacokinetic (PK) results for the Phase I clinical trial of the Company’s BICX104 implantable naltrexone pellet.
-
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
2/23/2023
BioCorRx Inc. announced today that Dr. Andrew Mallon, CSO and Grant Principal Investigator on the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), attended and presented a poster on BICX104.
-
BioCorRx to Present at Sequire Biotechnology Conference on February 2nd
1/27/2023
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Lourdes Felix, Chief Executive Officer, Chief Financial Officer, and Director of BioCorRx, and Brady Granier, President and Director of BioCorRx, will be presenting virtually at the Sequire Biotechnology Conference.
-
BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors
1/24/2023
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Harsha Murthy was appointed to the Company’s Board of Directors.
-
BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
1/19/2023
BioCorRx Inc. today announced an update from the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD), which is being developed under BioCorRx Pharmaceuticals, Inc.
-
BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.
11/22/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its board of directors has authorized the exploration of a potential spin-off of BioCorRx Pharmaceuticals, Inc., the Company’s controlled clinical stage drug development company, into a separate publicly traded company on a major exchange.
-
BioCorRx Provides Business Update for the Third Quarter of 2022
11/15/2022
BioCorRx Inc., a developer and provider of innovative treatment programs for substance abuse and related disorders, provided a business update for the third quarter ended September 30, 2022 and reported on recent corporate developments.
-
BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
10/13/2022
BioCorRx Inc. today announced that the last subject has been enrolled in the Phase I clinical trial of BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).
-
BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference
9/6/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourdes Felix, CEO, CFO, and Director of BioCorRx, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September 12th - 14th, 2022.
-
BioCorRx Provides Business Update for the Second Quarter of 2022
8/16/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business update for the second quarter ended June 30, 2022 and reported on recent corporate developments.
-
BioCorRx to Participate in the Benzinga All Access Event on July 15th
7/13/2022
BioCorRx Inc. (OTCQB: BICX) (the “Company”) , a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady Granier, President and Director of BioCorRx Inc. and CEO of BioCorRx Pharmaceuticals Inc., will be participating in the Benzinga All Access event taking place on July 15, 2022.